Audentes Therapeutics Gets $42.5M For Rare Diseases
San Francisco-based Audentes Therapeutics, which is developing treatments aimed at a number of rare diseases, said this week that it has raised $42.5M in a Series B financing round. The funding was led by Deerfield Management, and also included Sofinnova Ventures, Venrock, plus current investors OrbiMed, 5AM Ventures, and Versant Ventures. The company--led by Matthew Patterson--currently has two lead candidates focused on treatments of X-Linked Myotubular Myopathy and Pompe Disease.
posted on Friday, December 5, 2014 (Link to more information)
Related companies:
Audentes Therapeutics
Related stories:
> Audentes Therapeutics Sets IPO Pricing Range
> Audentes Therapeutics Prices IPO
> Arete Therapeutics Raises $35M
> Osprey Pharmaceutials Scores $11M
> Nuon Therapeutics Raises $27M
silicontap.com Home